{"id": "batch_req_ebACJnCQQTFnUPE8xh6DzYgQ", "custom_id": "1_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6b840366f0ecf6726caf6bdb62b6f70e", "body": {"id": "chatcmpl-9RR2BrjLaiRvyrKg5Y34ONUuG9iTM", "object": "chat.completion", "created": 1716325803, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an important medication in the treatment of certain types of cancer, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here are some key points you should know about Abemaciclib:\n\n### Mechanism of Action\n- **CDK4/6 Inhibitor**: Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in cell cycle regulation, and their inhibition can lead to reduced proliferation of cancer cells.\n\n### Indications\n- **Breast Cancer**: It is primarily used in combination with endocrine therapy (such as an aromatase inhibitor or fulvestrant) for the treatment of HR+, HER2- advanced or metastatic breast cancer. It can also be used as monotherapy in certain cases where patients have progressed on prior endocrine therapy and chemotherapy.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_iv7oE5gvPNGLnaFu4VUeisAB", "custom_id": "2_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "291297791fbf11a12e1b1b55d560af93", "body": {"id": "chatcmpl-9RR2BOmFYb36k4S10a7cN1ARLiKcb", "object": "chat.completion", "created": 1716325803, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Prostate Cancer**: Abiraterone is used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).\n\n### Mechanism of Action:\n- **CYP17 Inhibition**: Abiraterone works by inhibiting the enzyme CYP17A1 (17\u03b1-hydroxylase/C17,20-lyase), which is critical in the production of androgens. By blocking this enzyme, abiraterone reduces androgen production not only in the testes but also in the adrenal glands and the tumor itself.\n\n### Administration:\n- **Oral Intake**: Abiraterone is administered orally, typically in combination with a corticosteroid (prednisone or prednisolone)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_08lEzp06LkhiLGdzFZjEjtvt", "custom_id": "3_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4f7c84976a15ac8088a57b3707c526b4", "body": {"id": "chatcmpl-9RR2B51BMMzbCmoHNoADE8QLoegMF", "object": "chat.completion", "created": 1716325803, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about it:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Acalabrutinib is approved for the treatment of adult patients with CLL.\n2. **Mantle Cell Lymphoma (MCL)**: It is also indicated for the treatment of adult patients with MCL who have received at least one prior therapy.\n\n### Mechanism of Action:\n- **Bruton Tyrosine Kinase (BTK) Inhibitor**: Acalabrutinib works by inhibiting BTK, a protein that plays a crucial role in the survival and proliferation of B-cells. By blocking BTK, acalabrutinib helps to prevent the growth and spread of cancerous B-cells.\n\n### Administration:\n- **Oral Medication**: Acalabrutinib is administered orally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_HtmWjStgDeGqnNLRNC3bKFCm", "custom_id": "4_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dc58e41666f4224a77492c491265d7fd", "body": {"id": "chatcmpl-9RR2BwcJ2DsJc1nkSftSpfrUJW35h", "object": "chat.completion", "created": 1716325803, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic used primarily in the treatment of certain types of cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). Here are some key points you should know about Aclarubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Aclarubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme crucial for DNA replication and transcription.\n- **Inhibition of RNA Synthesis**: It also inhibits RNA synthesis, which can lead to apoptosis (programmed cell death) in rapidly dividing cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents for the treatment of AML.\n- **Other Hematologic Malignancies**: May be used in other types of leukemia or lymphomas, although its use is less common compared"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_27GEMJU2IKT5LiRZmLkrSy4Y", "custom_id": "5_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a30bcd17698c398b1f6a9031df6c4b7b", "body": {"id": "chatcmpl-9RR2C3uekBfoBa1u5ZOwWhpc9ppqs", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known as T-DM1 and marketed under the brand name Kadcyla, is an antibody-drug conjugate used in the treatment of HER2-positive breast cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Trastuzumab emtansine combines the HER2-targeted actions of trastuzumab (Herceptin) with the cytotoxic activity of the microtubule inhibitor DM1 (a derivative of maytansine).\n- **Targeting HER2**: Trastuzumab binds to the HER2 receptor on cancer cells, which is overexpressed in some breast cancers. This binding inhibits HER2 signaling and flags the cells for destruction by the immune system.\n- **Cytotoxic Payload**: Once trastuzumab emtansine is internalized by the cancer cell, DM1 is released, disrupting microt"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_cSBHoPvMEHa83mnvntOGd7nE", "custom_id": "6_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9416abc39f6aedbfc2593a89e8e18d1e", "body": {"id": "chatcmpl-9RR2CpezgaUXIsvrS9NhlyvYfrbIq", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Afatinib as a physician:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI)**: Afatinib is an irreversible inhibitor of the ErbB family of tyrosine kinases, which includes EGFR (epidermal growth factor receptor), HER2, and HER4. By inhibiting these receptors, Afatinib disrupts signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications\n- **NSCLC**: Afatinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations (e.g., exon 19 deletions or exon 21 L858R substitution mutations).\n- **Squamous Cell Carcinoma**: It is also indicated for the treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_gGi0g7egxYBuNFf1No8MYgV7", "custom_id": "7_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bdf75fe34ae9e1916612578b3cacbd79", "body": {"id": "chatcmpl-9RR2Cq4PisWONtoaUaR8c4Qgn2gUm", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a recombinant form of interleukin-2 (IL-2), a cytokine that plays a crucial role in the activation and proliferation of T-cells, which are essential for the immune response. Here are some key points you should know about Aldesleukin:\n\n### Indications\n- **Renal Cell Carcinoma (RCC):** Aldesleukin is primarily used for the treatment of metastatic renal cell carcinoma.\n- **Metastatic Melanoma:** It is also approved for the treatment of metastatic melanoma.\n\n### Mechanism of Action\n- **Immune Activation:** Aldesleukin stimulates the growth and activity of T-cells and natural killer (NK) cells, enhancing the body's immune response against cancer cells.\n\n### Administration\n- **Route:** It is administered intravenously.\n- **Dosing Schedule:** The dosing regimen can be complex and typically involves multiple cycles of treatment with rest"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_AO4lILAPbns97CngXVsrdnZS", "custom_id": "8_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "eca992c8a59cc0e2a258c0c00751c912", "body": {"id": "chatcmpl-9RR2D1TqhI2b7i6uBzF3C71Y0qxdV", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. Here are some key points you should know about Alectinib:\n\n### Mechanism of Action\n- **ALK Inhibitor**: Alectinib is a tyrosine kinase inhibitor that specifically targets and inhibits the activity of the ALK protein, which can drive the growth of cancer cells in certain types of NSCLC.\n\n### Indications\n- **NSCLC**: It is indicated for the treatment of patients with ALK-positive metastatic NSCLC. It is often used in cases where the cancer has progressed despite other treatments or as a first-line therapy.\n\n### Dosage and Administration\n- **Oral Administration**: Alectinib is taken orally, typically in capsule form.\n- **Dosing**: The standard dose is 600 mg twice daily with food. The exact dosage may vary based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_c45f7d0b45"}}, "error": null}
{"id": "batch_req_aIQ0Ui7lmb0BsyqzzagbPEYN", "custom_id": "9_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a7f59fcbf127f5ffb5fd264172b80d55", "body": {"id": "chatcmpl-9RR2CpvCJmtFe7d1UYATZUVAJMEgn", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are some key points you should know about Alemtuzumab:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):** Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia.\n2. **Multiple Sclerosis (MS):** It is also used in the treatment of relapsing forms of multiple sclerosis, typically in patients who have had an inadequate response to two or more other medications.\n\n### Mechanism of Action:\n- Alemtuzumab targets CD52, a protein present on the surface of mature lymphocytes. By binding to CD52, Alemtuzumab induces antibody-dependent cell-mediated cytolysis, leading to the depletion of these lymphocytes.\n\n### Administration:\n- **Route:** It is administered via intravenous infusion.\n- **Dosing:** The dosing regimen can vary depending on the condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_JRmizXXIgKJ1HXpz7IsglGKF", "custom_id": "10_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b5c8e2dd08a767d1f3061fd55774be78", "body": {"id": "chatcmpl-9RR2C2CaKBohV0QtuVCF2iqCcFakU", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and is used in various medical treatments, particularly in dermatology and oncology. Here are some key points you should know about ATRA:\n\n### Dermatological Uses:\n1. **Acne Treatment**: ATRA is commonly used topically to treat acne. It works by promoting cell turnover and preventing the formation of new comedones.\n2. **Photoaging**: It is also used to treat signs of photoaging, such as fine wrinkles, hyperpigmentation, and rough skin texture.\n3. **Psoriasis**: In some cases, ATRA can be used to manage psoriasis by reducing the proliferation of skin cells.\n\n### Oncological Uses:\n1. **Acute Promyelocytic Leukemia (APL)**: ATRA is a cornerstone in the treatment of APL, a subtype of acute myeloid leukemia. It induces differentiation of the immature leukemic cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_0J7vg5Fw0j6DN0KPCFzxeAOs", "custom_id": "1_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7bf5753245231ac59c0c8cd7a5ff7bdf", "body": {"id": "chatcmpl-9RR2C7wikfR9g8gE7lQfZC9oYLUIS", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an important medication used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Breast Cancer**: Abemaciclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It is often used in combination with endocrine therapy (e.g., aromatase inhibitors or fulvestrant) or as monotherapy in patients who have previously received endocrine therapy and chemotherapy.\n\n### Mechanism of Action:\n- **CDK Inhibitor**: Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in cell cycle progression, particularly the transition from the G1 phase to the S phase. By inhibiting these kinases, abemaciclib disrupts the proliferation of cancer cells.\n\n### Dosing:\n- **Oral Administration**: It is administered orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_aZC9h4T4HeKanuclQLjGfLN0", "custom_id": "2_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "73d935b6c9816417671aad127c532972", "body": {"id": "chatcmpl-9RR2CNEyqqprOQIekfReAF0q2ErEW", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer. Here are several key points you should know about it:\n\n### Indications\n1. **Prostate Cancer**: Abiraterone is particularly used in metastatic castration-resistant prostate cancer (mCRPC) and in some cases of metastatic high-risk castration-sensitive prostate cancer (mCSPC).\n\n### Mechanism of Action\n2. **Androgen Biosynthesis Inhibitor**: Abiraterone inhibits cytochrome P450 17A1 (CYP17A1), an enzyme critical for androgen biosynthesis. This leads to decreased production of testosterone and other androgens, which can fuel prostate cancer growth.\n\n### Administration\n3. **Dosage**: Typically, abiraterone is given as 1,000 mg orally once daily in combination with prednisone 5 mg orally twice daily. The prednisone helps to mitigate mineralocorticoid excess side effects such as hypertension,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_CMq2qrDfJYPMqeqvCOjRLDSo", "custom_id": "3_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9dc5e18451228af939cfe1816ef9d277", "body": {"id": "chatcmpl-9RR2CmeEEFdzaaS1rRh8Svenklq4t", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a selective Bruton\u2019s tyrosine kinase (BTK) inhibitor used primarily in the treatment of certain hematological malignancies. Here are key points that you should know about Acalabrutinib as a physician:\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**\n- **Small Lymphocytic Lymphoma (SLL)**\n- **Mantle Cell Lymphoma (MCL)** \u2013 particularly for patients who have received at least one prior therapy.\n\n### Mechanism of Action\n- Acalabrutinib works by selectively inhibiting BTK, a key enzyme in the B-cell receptor signaling pathway which is crucial for the proliferation and survival of malignant B-cells.\n\n### Dosage and Administration\n- The standard dose is 100 mg taken orally approximately every 12 hours.\n- It can be taken with or without food.\n- Capsules should be swallowed whole with water, not chewed, broken,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_vbTDDPW07t9Lzcwobp9NyJqK", "custom_id": "4_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7e2e44e78300cd2c5c525c299cb4a426", "body": {"id": "chatcmpl-9RR2CejFGVFHfTx9vKPwyGvN0SODE", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin (also known as aclacinomycin A) is an anthracycline antibiotic and chemotherapeutic agent primarily used in the treatment of various types of cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). Here are some key points you should be aware of:\n\n### Mechanism of Action\n- **Intercalation**: Aclarubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme critical for DNA replication and repair.\n- **Free Radical Generation**: It generates free radicals, leading to oxidative damage in cells.\n- **Apoptosis Induction**: The drug can induce apoptosis in cancer cells through various pathways.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents for the treatment of AML.\n- **Other Hematologic Malignancies**: May be used in certain other types of leukemias"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_zQ2XRNrcvN59CQyLqK20qvvz", "custom_id": "5_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "43eeef08c3f819dc865ccb1e77fa8d9c", "body": {"id": "chatcmpl-9RR2C8J87Km0p3rGxZziPE5KKo8Af", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by its brand name Kadcyla, is an antibody-drug conjugate used in the treatment of HER2-positive breast cancer. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**:\n   - Trastuzumab emtansine combines the HER2-targeted actions of trastuzumab with the cytotoxic activity of DM1 (a derivative of maytansine, a microtubule inhibitor).\n   - Trastuzumab binds to HER2 receptors on cancer cells, inhibiting cell proliferation and signaling for immune-mediated cell death.\n   - Once trastuzumab emtansine is internalized by the cancer cell, it releases DM1, which disrupts microtubule function, leading to cell cycle arrest and apoptosis.\n\n2. **Indications**:\n   - It's primarily indicated for patients with HER2-positive, metastatic breast cancer who have previously received trastuzumab and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_8SrGx0AN7bz5II5yMFCbmXdx", "custom_id": "6_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a5e1ab078573f6b3e72455abc2927267", "body": {"id": "chatcmpl-9RR2CGTa5pSIRyuWATpMYjsDtWZzl", "object": "chat.completion", "created": 1716325804, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is an oral, irreversible tyrosine kinase inhibitor (TKI) that targets the ErbB family of receptors, which includes EGFR (Epidermal Growth Factor Receptor), HER2 (Human Epidermal growth factor Receptor 2), and HER4. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Afatinib:\n\n### Indications:\n1. **NSCLC**: Afatinib is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with specific mutations in the EGFR gene (e.g., exon 19 deletions or exon 21 L858R substitution mutations).\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibition**: Afatinib works by irreversibly binding to and inhibiting the tyrosine kinase activity of EGFR, HER2, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_78SE5Kdc4OwMWcMvaMldKQGJ", "custom_id": "7_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ca6061cb0c9bdfb30cbc1975ec94113e", "body": {"id": "chatcmpl-9RR2DjCcvBreQKYYNSM5Iiros6DK8", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a recombinant human interleukin-2 (IL-2) used primarily in the treatment of metastatic renal cell carcinoma and metastatic melanoma. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Immunostimulatory Effects**: Aldesleukin stimulates the growth and activity of T-cells and natural killer (NK) cells, enhancing the immune system's ability to target and destroy cancer cells.\n\n### Indications:\n- **Metastatic Renal Cell Carcinoma**: Approved for the treatment of adults with this condition.\n- **Metastatic Melanoma**: Approved for the treatment of adults with this condition.\n\n### Administration:\n- **Route**: Typically administered via intravenous infusion.\n- **Dosing**: The dosing regimen can be complex and often involves multiple cycles of treatment, with hospitalization typically required for close monitoring due to potential severe"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_kEeKFtnepetvKSG2IUnZ1afm", "custom_id": "8_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2a473176a6dc7754bbbfe4029d0006f2", "body": {"id": "chatcmpl-9RR2Dq9q5IGhgQJVjz9vCLpeshlZI", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. Here are some key points you should know about Alectinib:\n\n### Mechanism of Action\n- **ALK Inhibitor**: Alectinib is a highly selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. It works by blocking the activity of the ALK protein, which is involved in the growth and spread of cancer cells.\n\n### Indications\n- **ALK-Positive NSCLC**: Alectinib is indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer. It is often used in cases where the cancer has spread to other parts of the body.\n\n### Dosage and Administration\n- **Standard Dosage**: The typical dosage is 600 mg taken orally twice daily.\n- **With Food**: It should"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_1yt4pQg5ASPG8UWCAu06qazs", "custom_id": "9_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "25a69ddc159ae29924f8cef4534acae2", "body": {"id": "chatcmpl-9RR2DWy4w7zArsOWwOFOeUYeHqmTR", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily for the treatment of certain types of cancer and autoimmune diseases. Here are key points you should know about Alemtuzumab:\n\n### Indications\n1. **Chronic Lymphocytic Leukemia (CLL)**: Alemtuzumab is FDA-approved for the treatment of B-cell CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.\n2. **Multiple Sclerosis (MS)**: Specifically for relapsing forms of multiple sclerosis (RMS). It is typically reserved for patients who have had an inadequate response to two or more MS therapies.\n\n### Mechanism of Action\n- Alemtuzumab targets the CD52 antigen present on the surface of mature lymphocytes. By binding to CD52, it induces antibody-dependent cell-mediated cytotoxicity (ADCC), leading to the depletion of these lymphocytes.\n\n### Administration\n- Alemtuzumab is administered via intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_uIPAUSNEdufYc2xW7Bxp8rwp", "custom_id": "10_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6fb67ffd220e64cf91effb2642cebba0", "body": {"id": "chatcmpl-9RR2DtWgrreag4h73ifrjmhI2N3Ss", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and is widely used in both dermatology and oncology. Here are key points you should know about ATRA:\n\n### Dermatological Use:\n1. **Mechanism of Action**: ATRA exerts its effects by binding to retinoic acid receptors (RARs) in the skin, which regulate gene expression and influence cellular processes such as differentiation, proliferation, and apoptosis. It helps normalize the shedding of dead skin cells and reduces the formation of comedones.\n\n2. **Indications**: It is commonly used topically to treat acne vulgaris, fine wrinkles, hyperpigmentation, and other signs of photoaging.\n\n3. **Application Advice**: The medication is typically applied once daily, in the evening, to avoid photodegradation. Patients should apply it to clean, dry skin and use a small amount to minimize irritation.\n\n4. **Side Effects**: Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_ClC9pXVWCDI864KY2jBTSzan", "custom_id": "1_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4d303ada7b88319090e338d4e5778364", "body": {"id": "chatcmpl-9RR2D3fCQJD274ev6US0pgx714f1q", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an important medication used in the treatment of certain types of cancer, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here's a detailed overview that could be helpful for you as a physician:\n\n### Mechanism of Action\nAbemaciclib is a targeted therapy that works as a CDK4/6 inhibitor. Cyclin-dependent kinases 4 and 6 (CDK4/6) play crucial roles in cell cycle progression, particularly the transition from the G1 phase to the S phase. By inhibiting these kinases, abemaciclib causes cell cycle arrest, thereby impeding the proliferation of cancer cells.\n\n### Indications\nAbemaciclib has several FDA-approved indications:\n1. **HR-positive, HER2-negative advanced or metastatic breast cancer:** Often used in combination with an aromatase inhibitor or fulvestrant.\n2. **As monotherapy:** For"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_c45f7d0b45"}}, "error": null}
{"id": "batch_req_TAbJ7ONn0lSkBj1CbethCSl7", "custom_id": "2_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9232956080861cc6f3b119fac2c80e56", "body": {"id": "chatcmpl-9RR2DNaFyFgaHokChP1ZSMkOGFS0b", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone is a potent medication primarily used in the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). As a physician, it's crucial to have a comprehensive understanding of its uses, mechanism of action, administration, side effects, and monitoring requirements. Here are key points to be aware of:\n\n### Mechanism of Action:\n- **Abiraterone** inhibits the enzyme CYP17A1 (17\u03b1-hydroxylase/C17,20-lyase), which is crucial for androgen biosynthesis. This inhibition reduces the production of testosterone and other androgens not only in the testes but also in the adrenal glands and within the tumor itself.\n\n### Indications:\n- Primarily indicated for the treatment of mCRPC.\n- Often used in combination with prednisone or prednisolone to help manage side effects and enhance efficacy.\n\n### Administration:\n- Given orally, often in a typical dose of 1,000 mg once daily.\n- Must be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_dlTcr4DvaHrWGZ6DEwVlkQxc", "custom_id": "3_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "648ae98dc3124d6685549ca771dc16ec", "body": {"id": "chatcmpl-9RR2EE3A8Ot5z5m2qhQudSkIumAef", "object": "chat.completion", "created": 1716325806, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, marketed under the brand name Calquence, is a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of certain B-cell malignancies. Here\u2019s a detailed summary of key points you should know about this medication:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**\n2. **Small Lymphocytic Lymphoma (SLL)**\n3. **Mantle Cell Lymphoma (MCL)** in patients who've received at least one prior therapy\n\n### Mechanism of Action:\nAcalabrutinib works by irreversibly binding to BTK, a crucial enzyme in the B-cell receptor signaling pathway. Inhibiting this enzyme disrupts signaling, which reduces the proliferation and survival of malignant B-cells.\n\n### Dosing:\n- The typical dose is 100 mg taken orally twice daily.\n- Tablets should be swallowed whole with water and can be taken without regard to food.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_eGnYzTaZ3yNXP58PlhumWMOL", "custom_id": "4_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "02467b6560f7a74834862f8630647e82", "body": {"id": "chatcmpl-9RR2DWP9YEAqng2LN9ldfiHBlgoRg", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin (often abbreviated as ACL or ACLA) is an anthracycline antibiotic and chemotherapeutic agent often used in the treatment of various types of cancer, particularly hematological malignancies. Here are some key points a physician should know about Aclarubicin:\n\n### Mechanism of Action:\n- **DNA Intercalation**: Aclarubicin intercalates into DNA, thereby inhibiting topoisomerase II and preventing DNA replication and transcription.\n- **Free Radical Formation**: It generates free radicals which can cause damage to cellular components, particularly DNA and cell membranes.\n\n### Indications:\n- Primarily used in treating hematologic cancers such as acute myeloid leukemia (AML).\n- Sometimes used in combination with other chemotherapeutic agents.\n\n### Administration:\n- Typically administered intravenously.\n\n### Dosage:\n- Dosages can vary based on the specific protocol and patient condition.\n- It is crucial to follow specific guidelines and protocols for administration to avoid overdose and minimize"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_CgabFYOf0P4HuBb0wzbbvctL", "custom_id": "5_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f69be0f9f7658202de965e4ed690aef4", "body": {"id": "chatcmpl-9RR2EIvA03K4Iz6EweHfkBSMIwmem", "object": "chat.completion", "created": 1716325806, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known as T-DM1 and marketed under the brand name Kadcyla, is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive breast cancer. Here are some critical aspects you should be aware of:\n\n### Mechanism of Action\n- **Trastuzumab Component:** Targets the HER2 receptor, a protein overexpressed in some breast cancers, enabling targeted delivery.\n- **Emtansine Component:** A cytotoxic agent (DM1) that binds to tubulin, inhibiting microtubule assembly and thereby exerting its antitumor effects.\n\n### Indications\n- **Adjuvant Treatment:** For early breast cancer patients who have residual invasive disease after neoadjuvant treatment with a taxane and trastuzumab.\n- **Metastatic Disease:** Specifically for patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane, either together or separately"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_5bNGR85laC6HU0P1i3V1lfp5", "custom_id": "6_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8d6a87add49d7e13dfa261aef3aee76d", "body": {"id": "chatcmpl-9RR2DDqfop0LuOEotuRQDw7WF3lYE", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is an orally administered, irreversible tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC). As a physician, it is crucial to understand the following aspects about Afatinib:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):**\n  - Approved for first-line treatment of patients with metastatic NSCLC with specific epidermal growth factor receptor (EGFR) mutations (e.g., exon 19 deletions or exon 21 (L858R) substitution mutations).\n  - Appropriate for patients whose tumors have developed resistance to other EGFR TKIs such as gefitinib or erlotinib due to the presence of specific mutations (e.g., T790M negative).\n\n### Mechanism of Action:\n- Afatinib binds irreversibly to EGFR, HER2, and HER4, inhibiting their tyrosine kinase activity and thus preventing the downstream signaling pathways that lead"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_gmggcH2eJEmJcCiWTIa1R8ny", "custom_id": "7_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8485cf80ec693eef36d3025f485a042b", "body": {"id": "chatcmpl-9RR2DJR0w7TsFpuHOtVTodDN4QSRE", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by the brand name Proleukin, is a synthetic form of interleukin-2 (IL-2), a cytokine that plays a crucial role in the activation and proliferation of T-cells, which are part of the body's immune response. Here is what you should know about Aldesleukin:\n\n### Indications:\n1. **Cancer Treatment**: Aldesleukin is primarily used in the treatment of metastatic renal cell carcinoma (RCC) and metastatic melanoma. It is administered to stimulate the body's immune system to attack cancer cells.\n  \n### Mechanism of Action:\n1. **Immune Activation**: Aldesleukin binds to IL-2 receptors on lymphocytes, stimulating the growth and activity of these immune cells, including natural killer (NK) cells and T-lymphocytes. This leads to an enhanced immune response against tumor cells.\n\n### Administration:\n1. **Routes of Administration**: Aldesleukin is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_1TPE6ebJeucmAwjFXyhkAgxa", "custom_id": "8_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8409f091ffb4e4ae11ae4c49c14a4cfd", "body": {"id": "chatcmpl-9RR2DH93l8b6XKqrPCvJJ2u5akAsd", "object": "chat.completion", "created": 1716325805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib, marketed under the brand name Alecensa, is an oral medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) rearrangements. As a physician, here are some key points you should know about Alectinib:\n\n### Mechanism of Action\n- **ALK Inhibition**: Alectinib is a potent and selective ALK inhibitor. It works by inhibiting the activity of the abnormal ALK protein responsible for the growth of cancer cells.\n\n### Indications\n- **NSCLC**: Alectinib is indicated for patients with ALK-positive metastatic non-small cell lung cancer. It can be used as a first-line therapy or in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Dosing and Administration\n- **Standard Dose**: The recommended dose is 600 mg taken orally twice daily with food.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_Z3ySqVHzmTXs1SVRF2XTDYuV", "custom_id": "9_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4a6739630c0f937ea773cb316fad6431", "body": {"id": "chatcmpl-9RR1GgwgEBnxs9mmE3ME8zdQOTgMO", "object": "chat.completion", "created": 1716325746, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab, marketed under the brand name Lemtrada and others, is a monoclonal antibody primarily used in the treatment of multiple sclerosis (MS) and chronic lymphocytic leukemia (CLL). Here's what you should know:\n\n### Indications:\n1. **Multiple Sclerosis (MS):**\n   - Specifically for relapsing-remitting multiple sclerosis (RRMS).\n   - Often reserved for patients who have had an inadequate response to two or more MS therapies due to the potential for serious side effects.\n\n2. **Chronic Lymphocytic Leukemia (CLL):**\n   - Approved for B-cell CLL.\n\n### Mechanism of Action:\n- Alemtuzumab targets CD52, a protein present on the surface of mature lymphocytes.\n- It binds to CD52 and leads to the destruction of these cells, reducing the immune system's ability to attack the nervous system in MS.\n\n### Dosage and Administration:\n1. **For Relapsing-Rem"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_e1dTwKSWU1smZdXn5BeQbYpk", "custom_id": "10_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8c2167022f3f0c339308e3ff0b1cd5c9", "body": {"id": "chatcmpl-9RR1GPTSeJBqYWsnhy0jyDLXJ7igX", "object": "chat.completion", "created": 1716325746, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A (retinoid) and is used in various medical contexts, most notably in dermatology and oncology. Here are key points you should know about ATRA:\n\n### Dermatology\n1. **Uses**:\n   - Commonly used in the treatment of acne vulgaris.\n   - Used to reduce fine wrinkles, mottled hyperpigmentation, and roughness of facial skin.\n   - Employed in the management of other dermatological conditions like psoriasis and photoaging.\n\n2. **Mechanism of Action**:\n   - Promotes cell turnover and sheds skin cells more rapidly.\n   - Reduces the formation of comedones and unblocks pores.\n   - Stimulates collagen production, which can help with fine lines and skin texture.\n\n3. **Application and Dosage**:\n   - Typically available as topical creams, gels, or solutions.\n   - Patients are usually advised to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_927397958d"}}, "error": null}
